AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00956930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75mg fixed dose
Study NCT01835184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib-s-malate
Description: Given PO
Study NCT01835184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: Given PO
Study NCT01835184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01835184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02812199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Composite Removable Sinus Stent
Description: Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.
Study NCT02812199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline-lidocaine
Description: adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)
Study NCT02812199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold saline wash
Description: nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
Study NCT01900964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen membrane
Description: A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
Study NCT00639028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ankle echography
Description: Ankle echography
Study NCT01795612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physical activity
Study NCT01615497 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based CBT with minimal clinical contact
Description: Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
Study NCT01975857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
Study NCT01975857 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Education
Description: This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
Study NCT03709576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
Study NCT03709576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant
Description: Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.
Study NCT03709576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
Study NCT02338908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
Study NCT00639028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ankle echography + stress radiography
Description: Ankle echography + stress radiography
Study NCT00639028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: stress radiography
Description: ankle stress radiography
Study NCT04707040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Exercise Program
Description: Neurocognitive Exercise Program (NEP) is defined as a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercise progression is performed from easy to difficult, and consist of simple and complex tasks. Different sports equipment (such as different sizes of balls, racket, tulle, pilates ball, eye band, rope, etc.) is used in motor coordination exercises where multiple extremities can be used in NEP. These materials are used during different exercises including cross-limb movements, throwing, jumping, walking, involving different cognitive tasks. The cognitive task used and the degree of difficulty of the task are provided by different visual (colored cards, numbered cards, gestures, etc.) or auditory (keywords, ring signal, etc.) signs. For example, showing a red card might indicate throwing a ball with the left hand, while showing a blue card indicates throwing a ball with the right hand and walking forward
Study NCT04176029 — intervention group
Intervention type: DEVICE
Intervention: lung ultrasound
Description: Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.
Study NCT02357732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02357732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Study NCT02338908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
Study NCT02338908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TrP-DN
Description: In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
Study NCT02009384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: administration of IV ipilimumab for up to 4 cycles
Study NCT02530047 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MSC-INFβ
Description: MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.~Starting dose: 10\^5 MSC/kg once a week for 4 treatments.
Study NCT02530047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Symptom questionnaire completed once a week for 4 weeks.
Study NCT01402427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
Study NCT01402427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intraarterial administration of 10 mL saline.
Study NCT03015480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote counseling
Description: For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
Study NCT02595645 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polypectomy and NGS
Description: NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
Study NCT04397770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study NCT04397770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib mesylate
Description: apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
Study NCT04397770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Injection
Description: Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
Study NCT03838809 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surface electromyography-biofeedback
Description: Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
Study NCT03838809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surface electromyography-biofeedback
Description: Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
Study NCT02225613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual protocol
Study NCT02225613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spa protocol
Study NCT03231683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
Study NCT03231683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
Study NCT02357732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Study NCT03423056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative exercise program
Description: Individualized aerobic training program developed by physical therapist using Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks. Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed between 50 to 70% of the maximum heart rate and will be carried on a treadmill or in a stationary bicycle.
Study NCT03343795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral progesterone
Description: daily
Study NCT03343795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intramuscular progesterone
Description: every week
Study NCT02152332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Therapeutic Dose
Description: JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
Study NCT00751413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0633
Description: A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
Study NCT03095287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alphanate
Description: Bolus IV injection.
Study NCT00582517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compass Universal Hinge External Fixator
Description: Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
Study NCT00582517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive External Knee Brace
Description: For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
Study NCT02152332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 - Supratherapeutic Dose
Description: JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
Study NCT02152332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Matched Placebo
Description: JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
Study NCT02152332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg on Day 7 in all treatment sequence.
Study NCT02152332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Matched Placebo
Description: Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
Study NCT03060421 — intervention group
Intervention type: DEVICE
Intervention: Aquamid reconstruction
Description: Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
Study NCT04008017 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Eosinophilic Cationic Protein biomarker
Description: 3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
Study NCT03766425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: subconjunctival injection
Study NCT03766425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: subconjunctival injection
Study NCT02373319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CV-screening-1 plus personalized
Description: Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
Study NCT02373319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CV-screening-2 plus personalized
Description: Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
Study NCT02373319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CV-screening-1 plus standard
Description: Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
Study NCT02373319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CV-screening-2 plus standard
Description: Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
Study NCT02042664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYETTA treatment
Study NCT02042664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformine
Study NCT04057222 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Only propose water and wait for need to void
Study NCT00280553 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bupivicaine
Description: PCA and bupivicaine infusion for up to five days
Study NCT00280553 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saline infusion
Description: PCA and pump with saline infusion for up to five days
Study NCT00385346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
Study NCT02993380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stir-fried olive oil group
Description: Stir-fried olive oil group taking food with extra-virgin olive oil in stir fried food or any food with olive oil in heated under 150 degrees of celsius minimal dose per week is 30gram, providing amount of olive oil with meals is 10gram, three times in a weeks
Study NCT02993380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural olive oil group
Description: Natural olive oil group taking food with extra-virgin any food with olive oil in , minimal dose per week is 30grams, providing amount of olive oil with meals is 10gram, three times in a weeks
Study NCT02265783 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nellcor USB Pulse Oximeter Monitor Interface Cable
Description: Volunteers are subjected to certain simulated, sensor removal conditions known to represent challenges to the sensor-off feature. Such conditions include exposing the sensor to an ambient light source, sensor slipping off the finger with the light emitter and detector facing each other or a sensor slipping off under a blanket.
Study NCT03892694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RejuvenAir System
Description: Bronchial metered cryospray using RejuvenAir® System.
Study NCT03892694 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham control procedure
Study NCT02291263 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV/IPV (6 weeks)
Description: bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age
Study NCT02291263 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV/IPV (14 weeks)
Description: bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age
Study NCT02291263 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV/IPV (6 & 14 weeks)
Description: bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
Study NCT04381962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Capsule
Description: Azithromycin 500 mg OD PO 14 days
Study NCT01841866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LMA removal
Study NCT01841866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LMA removal
Study NCT03204630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lfer
Description: Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
Study NCT03204630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifido
Description: Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
Study NCT03204630 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard infant formula
Study NCT01061008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post operative progressive handgrip exercise
Description: As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention
Study NCT01061008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
Study NCT01841619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIg
Description: All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in \<25% subjects, the subjects will be re-treated by the standard protocol.
Study NCT00395967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Description: Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
Study NCT00379951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem sodium
Description: ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
Study NCT01781455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Study NCT02204631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head and Neck Educational Handbook
Study NCT02542176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze-dried Whole Grape Powder
Description: 60 g of whole grape powder for 4 weeks